However, while CDK4/6 inhibitors significantly extend both progression-free survival (PFS) and overall survival (OS) of women with advanced/metastatic HR+ breast cancer, the majority of these patients eventually progress and succumb to their disease [2–4], calling for the implementation of combinatorial regimens with superior therapeutic activity (and acceptable toxicity). Here, CDK4 is linked to breast carcinoma.